



Nagelamides M and N, new bromopyrrole alkaloids from sponge *Agelas* species

Takaaki Kubota^a, Atsushi Araki^a, Junji Ito^b, Yuzuru Mikami^b, Jane Fromont^c, Jun'ichi Kobayashi^{a,*}

^a Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan

^b Medical Mycology Research Center, Chiba University, Chiba 260-0856, Japan

^c Western Australian Museum, Locked Bag 49, Welshpool DC, WA 6986, Australia

ARTICLE INFO

Article history:

Received 11 August 2008

Received in revised form

15 September 2008

Accepted 15 September 2008

Available online 24 September 2008

ABSTRACT

Two new bromopyrrole alkaloids, nagelamides M (**1**) and N (**2**), have been isolated from an Okinawan marine sponge *Agelas* species, and the structures and stereochemistry were elucidated from the spectroscopic data. Nagelamide M (**1**) is a novel bromopyrrole alkaloid possessing a 2-amino-octahydro-pyrrolo[2,3-*d*]imidazole ring with a taurine unit, while nagelamide N (**2**) is a new bromopyrrole alkaloid possessing a 2-amino-tetrahydroimidazole-4-one ring with a taurine unit and 3-(dibromopyrrole-2-carboxamido)propanoic acid moiety. Nagelamides M (**1**) and N (**2**) exhibited antimicrobial activity.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Bromopyrrole alkaloids are known to be one of the most common metabolites contained in marine sponges.¹ During our search for bioactive substances from marine organisms, we previously isolated several bromopyrrole alkaloids with unique cyclic skeletons from sponges of *Agelas* or *Hymeniacidon* sp.² More recently, two new bromopyrrole alkaloids, nagelamides M (**1**) and N (**2**), have been isolated from an Okinawan marine sponge *Agelas* sp. (SS-1134). Here we describe the isolation and structure elucidation of **1** and **2**.


2. Results and discussion

The sponge *Agelas* sp. (SS-1134) collected off Seragaki beach, Okinawa, was extracted with MeOH. BuOH-soluble materials of the extract were subjected to silica gel and C₁₈ column chromatographies followed by C₁₈ HPLC to yield nagelamides M (**1**, 0.00069%, wet weight) and N (**2**, 0.0016%) together with known related alkaloids, tauroacidin A,³ taurodispacamide A,⁴ and nagelamides C⁵ and K.²

The ESIMS spectrum of nagelamide M (**1**) showed the pseudo-molecular ion peaks at *m/z* 529, 529, and 531 (1:2:1), indicating the presence of two bromine atoms, and the molecular formula of **1** was revealed to be C₁₃H₁₈N₆O₅Br₂S₁ by HRESIMS data [*m/z* 526.9340 (M–H)[–], Δ –0.8 mmu]. The UV absorption [λ_{max} 275 nm (ε 18,000)] was attributed to a pyrrole chromophore,⁶ while the IR absorption (1684 cm^{–1}) indicated the existence of amide carbonyl functionality.

The ¹H NMR (Table 1) spectrum included five D₂O-exchangeable signals (δ_H 12.65, 9.02, 8.64, 8.30, and 7.95) attributed to amino and/or amide protons. The ¹³C NMR (Table 1) spectrum disclosed 13 signals due to one amide carbonyl carbon, four sp² quaternary carbons, one sp² methine, one sp³ quaternary carbon, two sp³ methine, and four sp³ methylenes. Among the ¹³C signals of **1**, one amide carbonyl (159.10), three sp² quaternary carbons (127.98, 104.41, and 97.91), and one sp² methine (δ_C 113.29) were ascribed to a 2,3-dibromopyrrole carbonyl moiety (N-1–C-6) by comparison with those of known bromopyrrole alkaloids,² while one sp³ quaternary carbon (δ_C 94.36) and one sp³ methine (δ_C 81.26) were assigned as those bearing two hetero atoms such as oxygen and nitrogen atoms.

Detailed analyses of the ¹H–¹H COSY and HMQC spectra disclosed three structural fragments, N-7 to C-10, C-2' to C-3', and N-14 to C-15. The presence of a 2,3-dibromopyrrole moiety was suggested by HMBC cross-peaks of NH-1 to C-3 and C-4, and H-4 to C-2 and C-5 (Fig. 1). The NOESY correlation for NH-7/H-4 indicated that the 2,3-dibromopyrrole moiety was attached to N-7 through an amide bond. The presence of a 2-amino-octahydro-pyrrolo[2,3-*d*]imidazole ring was deduced from analysis of the HMBC spectrum of **1**. Connections among C-10, N-12, and C-15 via C-11 were implied by HMBC cross-peaks for H₂-10 and H-15 to C-11, and NH-12 to C-15. HMBC correlations for NH-12, NH-14, and H-15 to C-13, and



* Corresponding author. Tel.: +81 11 706 3239; fax: +81 11 706 4989.

E-mail address: jkobay@pharm.hokudai.ac.jp (J. Kobayashi).

Table 1¹H and ¹³C NMR data of nagelamide M (**1**) in DMSO-*d*₆

Position	δ_{H}		δ_{C}
1	12.65	brs	—
2	—		104.41
3	—		97.91
4	7.02	brs	113.29
5	—		127.98
6	—		159.10
7	8.30	brdd 7.7, 4.2	—
8a	3.67	m	37.40
8b	3.18	m	—
9	2.94	m	59.50
10a	2.11	dd 12.1, 4.7	40.67
10b	1.77	brt 11.5	—
11	—		94.36
12	9.02	brs	—
13	—		157.54
13-NH ₂	7.95 (2H)	brs	—
14	8.64	brs	—
15	4.93	brs	81.26
2'a	3.16	m	48.34
2'b	2.86	m	—
3'a	2.82	m	40.78
3'b	2.72	m	—



NH-12 to C-15 indicated the connection of N-12 and N-14 via C-13. The connectivity of C-9 and C-15 through N-1' was implied by the HMBC cross-peak of H-15 to C-9, while HMBC correlations for NH-14 to C-11 indicated the connection of C-11 and N-14 via C-15. In addition, NOESY correlations for H₂-8/H-2' and H-15/H₂-2' suggested that a taurine unit was attached to N-1'. Thus, the gross structure of nagelamide M was elucidated to be **1**.

Relative stereochemistry of the bicyclic system in **1** was deduced from *J*-values and NOESY correlations as shown in Figure 2. The NOESY correlation for H-10b/H-15 indicated that H-10b and H-15 was α -oriented, while NOESY cross-peaks of H-9/H-10a, and H-10a/NH-12 suggested that these hydrogen atoms were β -oriented. The cis ring junction of the bicyclic ring system and an α -orientation of 11-OH were implied by data described above.

The ESIMS spectrum of nagelamide N (**2**) showed the pseudo-molecular ion peaks at *m/z* 557, 559, and 561 (1:2:1), suggesting the presence of two bromine atoms. The molecular formula of **2** was revealed to be C₁₃H₁₅N₆O₇Br₂S₁ from HRESIMS data [*m/z* 556.9105 (M-H)[−], Δ +1.5 mmu]. The UV absorption [λ_{max} 275 nm (ϵ 10,000)] indicated the presence of pyrrole chromophore, while IR absorptions (3388, 1700, and 1678 cm^{−1}) suggested the existence of hydroxyl and carbonyl functionalities.

The ¹H NMR (Table 2) spectrum included six D₂O-exchangeable signals (δ_{H} 12.75, 9.84, 9.15, 9.07, 8.31, and 7.92) attributed to amino and/or amide protons. The ¹³C NMR (Table 2) spectrum disclosed 13 signals due to seven sp² quaternary carbons, one sp² methine, one sp³ methine, one sp³ quaternary carbon, and three sp³ methylenes.

Inspection of the ¹H–¹H COSY and HMQC spectra of **2** revealed two structural fragments, N-7 to C-9 and N-1' to C-3'. The presence

**Figure 1.** Selected 2D NMR correlations for nagelamide M (**1**).**Figure 2.** Selected NOESY correlations and relative stereochemistry for the bicyclic core in nagelamide M (**1**).

of 2,3-dibromopyrrole moiety was suggested by HMBC cross-peaks of NH-1 to C-3 and C-4, and H-4 to C-2 and C-5. The ROESY correlation for NH-7/H-4 indicated that the 2,3-dibromopyrrole moiety was attached to NH-7 through an amide bond. The HMBC correlation for H-9 to C-10 indicated that a carboxy group was attached to C-9. The presence of an aminoimidazole ring was deduced from HMBC correlations for NH-12 to C-11, C-13, and NH-12 and NH-14 to C-15, and ROESY cross-peaks for 13-NH₂/NH-12 and NH-14. The HMBC correlation for H-9 to C-11 and the ROESY cross-peak of NH-1'/H-9 revealed that both C-9 and NH-1' were attached to C-11. Thus, the gross structure of nagelamide N was assigned as **2** (Fig. 3).

The relative stereochemistry of **2** was deduced from ROESY data. The relative stereochemistry for C-9 and C-11 in **2** was elucidated by ROESY correlations of NH-1'/H-8a and H-9, and NH-12/H-8b as shown in Figure 4.

A plausible biogenetic path for nagelamides M (**1**) and N (**2**) is proposed as shown in Scheme 1. Nagelamide M (**1**) could be produced by oxidation of intermediate **A**, which might be derived from taurodispacamide **A**⁴ through cyclization, while nagelamide N (**2**) could be generated from hydrolysis and oxidation of intermediate **B**, which might be derived from taurodispacamide **A** through Baeyer–Villiger oxidation and cyclization.

Nagelamide M (**1**) is a novel bromopyrrole alkaloid possessing a 2-amino-octahydropyrrolo[2,3-*d*]imidazole ring with a taurine unit, while nagelamide N (**2**) is a new bromopyrrole alkaloid consisting of a 2-amino-tetrahydroimidazole-4-one ring with a taurine unit and 3-(dibromopyrrole-2-carboxamido)propanoic acid moiety. Nagelamides M (**1**) and N (**2**) showed inhibitory activity against *Aspergillus niger* (MIC, 33.3 μ g/mL, each).

Table 2¹H and ¹³C NMR data of nagelamide N (**2**) in DMSO-*d*₆

Position	δ_{H}		δ_{C}
1	12.75	brs	—
2	—		105.07
3	—		98.05
4	6.89	s	113.12
5	—		127.91
6	—		159.09
7	8.31	brt	—
8a	3.02	m	36.57
8b	3.29	m	—
9	3.12	dd 12.2, 4.0	51.91
10	—		172.13
11	—		90.40
12	9.07	brs	—
13	—		167.55
13-NH ₂	7.92 (2H)	brs	—
14	9.15	brs	—
15	—	brs	178.60
1'	9.84	brt	—
2'a	3.58		40.24
2'b	3.68	s	—
3'	3.82 (2H)	t 7.6	49.17




Figure 3. Selected 2D NMR correlations for nagelamide N (2).




Figure 4. Rotation model for C-9/C-11 bond of nagelamide N (2).

3. Experimental section

3.1. General experimental procedures

Optical rotation was recorded on a JASCO P-1030 polarimeter. IR and UV spectra were recorded on a Shimadzu UV-1600PC and a JASCO FT/IR-5300 spectrophotometers, respectively. ^1H , ^{13}C and 2D NMR spectra were measured on a JEOL ramuda-400 spectrometer


and Bruker AMX-600 spectrometer using 5 and 2.5 mm micro cells (Shigemi Co., Ltd.) for $\text{DMSO}-d_6$. Positive mode ESIMS spectra were measured at -80 V as a focus voltage using a sample dissolved in MeOH with flow rate of $200\text{ }\mu\text{L}/\text{min}$. Antimicrobial activities were determined by a microbroth dilution method using BHI medium.

3.2. Sponge description

The sponge (SS-1134) *Agelas* sp. (order, Agelasida, family Agelasidae) was collected off Seragaki, Okinawa, and kept frozen until used. The sponge was open textured sponge with convoluted surface with numerous superficial depressions and occasional oscules. The sponge has a fine ridged pattern over the surface with large apical oscules approximately 5 mm wide. The surface patterning gives a 'brain-like' appearance. The sponge has a dense internal structure and is firm and compressible. Skeleton is reticulate with fiber development, with primary fibers cored by verticillate acanthostyles, 4 spicules across, fibers are $130\text{ }\mu\text{m}$ wide and mesh spaces are approximately $500\text{ }\mu\text{m}$ wide. Secondary fibers form a tight mesh and are either cored or unispicular. Spicules are verticillate spined acanthostyles, thick, slightly curved $250\times 20\text{ }\mu\text{m}$, some thin forms occur. The voucher specimen was deposited at Graduate School of Pharmaceutical Sciences, Hokkaido University.

3.3. Extraction and isolation

The sponge (SS-1134, 0.70 kg, wet weight) was extracted with MeOH ($2\text{ L}\times 2$), and the extract was partitioned between BuOH ($500\text{ mL}\times 3$) and H_2O (500 mL). Part (7.63 g) of BuOH-soluble materials (10.63 g) were subjected to a silica gel column ($\text{CHCl}_3/\text{MeOH}/\text{AcOH}$) and then a C_{18} column (Cosmosil 140 C_{18} PREP, Nakarai Tesque Inc.; eluent, $\text{MeOH}/\text{H}_2\text{O}/\text{CF}_3\text{CO}_2\text{H}$, 80:20:0.1) to give a crude fraction of alkaloids. This fraction was separated by C_{18} MPLC (KUSANO C.I.G.; Kusano Science Corp.; eluent, $\text{MeOH}/\text{H}_2\text{O}/\text{CF}_3\text{CO}_2\text{H}$, 45:55:0.1 to 90:10:0.1 in 90 min; flow rate, $3.5\text{ mL}/\text{min}$). A part of the fraction containing 1 and 2 were purified by C_{18} HPLC



Scheme 1. Plausible biogenetic path for nagelamides M (1) and N (2).

[YMC Hydrosphere C18, YMC Co., Inc., 10×250 mm; eluent, CH₃CN/H₂O/CF₃CO₂H, 20:80:0.1; flow rate, 2.5 mL/min; UV detection at 255 nm] to afford nagelamide N (**2**, 3.5 mg, 0.0016%, wet weight) and a fraction containing **1**. Further purification of the fraction containing **1** by C₁₈ HPLC [YMC Hydrosphere C18, YMC Co., Inc., 10×250 mm; eluent, CH₃CN/H₂O/CF₃CO₂H, 15:85:0.1 to 25:75:0.1 in 20 min; flow rate, 2.5 mL/min; UV detection at 255 nm] afforded nagelamide M (**1**, 1.5 mg, 0.00069%).

3.4. Nagelamide M (**1**)

Colorless amorphous solid; $[\alpha]_D^{24}$ −7 (c 0.1, MeOH); UV (MeOH) λ_{\max} 275 nm (ϵ 18,000); IR (KBr) ν_{\max} 3404, 1684, 1635, 1200, and 1044 cm^{−1}; ESIMS (neg.) m/z 527, 529, and 531 [1:2:1, (M−H)[−]]; HRESIMS (neg.) m/z 526.9340 [(M−H)[−], calcd for C₁₃H₁₇N₆O₅⁷⁹Br₂S, 526.9348].

3.5. Nagelamide N (**2**)

Colorless amorphous solid; $[\alpha]_D^{24}$ −1 (c 0.1, MeOH); UV (MeOH) λ_{\max} 275 nm (ϵ 10,000); IR (KBr) ν_{\max} 3388, 1700, 1678, 1638, 1206, and 1045 cm^{−1}; ESIMS (neg.) m/z 557, 559, and 561 [1:2:1,

(M−H)[−]]; HRESIMS (neg.) m/z 556.9105 [(M−H)[−], calcd for C₁₂H₁₅N₆O₇⁷⁹Br₂S, 556.9090].

Acknowledgements

Authors thank Ms. S. Oka and Mr. T. Hirose, Center for Instrumental Analysis, Hokkaido University, for measurements of ESIMS and NMR spectra, respectively. This work was partly supported by grants from the Uehara Memorial Foundation, the Yakult Bio-Science Foundation, and Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References and notes

1. Blunt, J. W.; Copp, B. R.; Hu, W.-P.; Munro, M. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2008**, 25, 35–94.
2. Araki, A.; Kubota, T.; Tsuda, M.; Mikami, Y.; Fromont, J.; Kobayashi, J. *Org. Lett.* **2008**, 10, 2099–2102 and references therein.
3. Kobayashi, J.; Inaba, K.; Tsuda, M. *Tetrahedron* **1997**, 53, 16679–16682.
4. Fattorusso, E.; Tagliatela-Scafati, O. *Tetrahedron Lett.* **2000**, 41, 9917–9922.
5. Endo, T.; Tsuda, M.; Okada, T.; Mitsuhashi, S.; Shima, H.; Kikuchi, K.; Mikami, Y.; Fromont, J.; Kobayashi, J. *J. Nat. Prod.* **2004**, 67, 1262–1267.
6. (a) Forenza, S.; Minale, L.; Riccio, R.; Fattorusso, E. *J. Chem. Soc., Chem. Commun.* **1971**, 1129–1130; (b) Gracia, E. E.; Benjamin, L. E.; Fryer, R. I. *J. Chem. Soc., Chem. Commun.* **1973**, 78–79.